|
Approve Suite Weekly · Tuesday, October 20, 2026 · read online
8-K: Rapport Therapeutics, Inc. mentions topline results
Rapport Therapeutics announces positive Phase 2 results for RAP-219 in bipolar mania. Positive Phase 2 topline results demonstrating clinical proof-of-concept for RAP-219 in acute mania associated with bipolar I disorder. The trial met its primary endpoint with statistically significant placebo-adjusted improvement in YMRS score at Week 3 and good tolerability, supporting advancement toward later-stage development. FDA finalizes guidance on postapproval manufacturing changes for biosimilar products. This final guidance clarifies regulatory expectations for postapproval manufacturing changes to biosimilar and interchangeable biosimilar products licensed under the PHS Act. It replaces the draft guidance issued July 23, 2024, providing industry with definitive answers on compliance requirements for manufacturing modifications. The pattern? 8-K filings led the week with 16, ahead of trial status changes (12), out of 39 counted.
This week's author: Ryan Burke, Approve Suite
8-K: Rapport Therapeutics, Inc. mentions topline results
8-K · Rapport Therapeutics Inc.
Rapport Therapeutics announces positive Phase 2 results for RAP-219 in bipolar mania.
Why it matters. Positive Phase 2 topline results demonstrating clinical proof-of-concept for RAP-219 in acute mania associated with bipolar I disorder. The trial met its primary endpoint with statistically significant placebo-adjusted improvement in YMRS score at Week 3 and good tolerability, supporting advancement toward later-stage development.
What to watch. Items 1.01, 2.02 and 8.01 carry the material terms; the exhibits hold the detail.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers; Guidance for Industry; Availability
Final guidance
FDA finalizes guidance on postapproval manufacturing changes for biosimilar products.
Why it matters. This final guidance clarifies regulatory expectations for postapproval manufacturing changes to biosimilar and interchangeable biosimilar products licensed under the PHS Act. It replaces the draft guidance issued July 23, 2024, providing industry with definitive answers on compliance requirements for manufacturing modifications.
What to watch. Final guidance applies on publication. If a draft it replaces was followed, the changed sections are the ones to read.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
Efficacy supplement approved: Anktiva (nogapendekin alfa inbakicept-pmln) — Altor Bioscience, Llc, An Indirect Wholly-Owned Su, BLA 761336
Approval · Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
FDA approves efficacy supplement for Anktiva (nogapendekin alfa inbakicept-pmln).
Why it matters. Approval of an efficacy supplement expands or clarifies the clinical benefits of Anktiva in its approved indication. This represents regulatory recognition of additional efficacy data for a marketed therapeutic.
What to watch. The label and the approval letter post to Drugs@FDA; launch timing usually follows in an 8-K.
READ MORE → · open in Approve Suite
By the numbers
Inspections: 0 NAI · 0 VAI · 0 OAI Warning letters: 0 Class I recalls: 0 (Class II 0, Class III 0) Trial stops and status changes: 12 (results posted: 6) Raises: 8, $194M disclosed
93 events, down 80% on the prior 7 days.
204 listed companies report under 12 months of runway.
Signals
1. 8-K: Disc Medicine, Inc. mentions topline results 8-K · Disc Medicine, Inc app 2. 8-K: Veradermics, Inc mentions topline results 8-K · Veradermics, Inc. app 3. NCT07677865: GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation — Now WITHDRAWN West China Hospital app 4. Safety communication: Diagnostic Ultrasound System Correction: Philips Ultrasound Issues Updated Use Instructions for Lumify Diagnostic Ultrasound System Philips Ultrasound, LLC app 5. Drug shortage current: Sodium Acetate Injection (Fresenius Kabi USA, LLC) Fresenius Kabi USA, LLC app 6. Drug shortage current: Dexamethasone Sodium Phosphate Injection (Fresenius Kabi USA, LLC) Fresenius Kabi USA, LLC app
Why this exists
Approve Suite Weekly exists so a QA or RA lead can read one email on Tuesday and know what FDA, the SEC and ClinicalTrials.gov published in the past week. Every line links to its public source; nothing here is advice.
Sponsor this email
How was this week's email?
AwesomeDecentNot great
| 